Blood Analyzers in Massachusetts

Diamond Diagnostics Inc. is a specialized clinical laboratory instrumentation and consumables supplier based in Holliston, Massachusetts, founded in 1996. The company manufactures, remanufactures, and supplies new and refurbished chemistry analyzers, electrolyte analyzers, immunoassay systems, blood gas analyzers, coagulation analyzers, hematology analyzers, and molecular analyzers. With approximately 80 employees and ~$19M annual revenue, Diamond offers over 500 consumable products including reagents, quality controls, and electrodes. The company's proprietary Down-To-Frame® refurbishment process restores equipment to like-new condition. Most products hold FDA clearance and CE approval. Diamond provides comprehensive field service, depot service, preventive maintenance, remote support, control assay, and refurbishment services to clinical laboratories and hospitals globally. ISO 9001:2015 and ISO 13485:2016 certified, the company also offers OEM and contract manufacturing for third-party organizations.

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.

Phoenix Diagnostics is an in vitro diagnostics (IVD) manufacturer specializing in consumables for blood gas, electrolyte, and chemistry analyzers. The company manufactures quality controls, calibrators, reagents, and electrodes with over 50 years of industry experience. Product coverage encompasses more than 50 analyzer models from major manufacturers including Siemens (Bayer/Corning), Radiometer, Werfen (IL), Abbott Point of Care, Beckman Coulter, Roche Diagnostics, IDEXX Laboratories, Medica Corporation, Nova Biomedical, and Tokyo-Boeki. Phoenix manufactures over 90% of its product line in-house, enabling direct technical support and rapid custom solutions. The company serves clinical laboratories, hospitals, and international dealers and distributors. Product lines include blood gas and ISE controls, linearity controls, and electrodes compatible with major clinical laboratory platforms. The company offers private label contracting and custom manufacture capabilities, along with a Rapid-Stat QC program. No specific FDA, ISO, or other regulatory certifications are mentioned on the website.

SiPhox Health is a Burlington, Massachusetts-based health diagnostics company specializing in silicon photonic biosensor technology for at-home blood testing and biomarker analysis. Founded in 2020 and backed by Y Combinator, Khosla Ventures, and Intel Capital, the company has delivered over 300,000 biomarker test results. SiPhox's proprietary EasyDraw kit enables painless upper-arm blood collection without needles or lab visits, with samples processed at CLIA-certified labs. The platform analyzes up to 60 biomarkers across cardiovascular, metabolic, hormonal, thyroid, liver, kidney, inflammation, and nutritional health. Beyond testing, SiPhox provides a centralized health dashboard with wearable integration (Apple Watch, Oura Ring, Fitbit), personalized supplement recommendations, lifestyle coaching, telehealth support, and an AI assistant (Sai) for result interpretation. The company targets chronic disease prevention and health optimization through evidence-based biomarker tracking and actionable insights.

Harvard Bioscience Inc is a holding company and distributor of laboratory and research equipment serving academic institutions, contract research organizations (CROs), pharmaceutical, and biotech companies. The company operates through multiple subsidiary brands including Data Sciences International (DSI), BTX Electroporation Systems, Multi Channel Systems (MCS), Biochrom, HEKA, Harvard Apparatus, Panlab, Warner Instruments, CMA Microdialysis, and Hugo Sachs Elektronik. Product portfolio encompasses electrophysiology systems (patch clamp amplifiers, multielectrode arrays, Ussing chambers), spectrophotometers and colorimeters (Ultrospec series, Biowave), amino acid analyzers, telemetry and behavioral monitoring systems, electroporation devices, and isolated organ perfusion systems. The company serves discovery, production, and regulatory compliance workflows for life-saving therapeutic development. Products include the INCUB8 multiwell MEA system for optical and electrophysiological recording, HEKA EPC 10 USB 3.0 patch clamp amplifier, IntraCell laser-based optoporation system, VivaMARS activity monitoring platform, Ponemah software (GLP and 21 CFR Part 11 compliant), continuous glucose telemetry for rodents, and various UV-Vis spectrophotometric instruments. The company actively participates in major scientific conferences including SfN, APS, ECS, and ISSCR, and maintains active engagement in neuroscience, cardiac, and translational research communities.

LGC Clinical Diagnostics is a global manufacturer specializing in quality management tools, reagent components, biological materials, and diagnostic solutions for the in vitro diagnostics (IVD) and life sciences sectors. As a division of the LGC Group, the company integrates expertise from multiple brands including Technopath Clinical Diagnostics, SeraCare, Biochemical Diagnostics, Kova International, Maine Standards, and The Native Antigen Company. The company manufactures comprehensive portfolios of catalog and custom-developed diagnostic quality solutions, serving over 27,500 customers worldwide including IVD manufacturers, clinical laboratories, biopharmaceutical companies, and academic institutions. Products and services include quality controls, reference materials, linearity and calibration verification solutions, antigens and antibodies, drugs of abuse quality controls, urinalysis quality controls, and external quality assessment (EQA) proficiency testing programs. All facilities are FDA-registered and certified to ISO 13485 and ISO 9001 standards, demonstrating commitment to quality and regulatory compliance throughout the diagnostic pipeline from early research to routine clinical use.

Hamilton Thorne is a leading manufacturer of precision laser systems, CASA (Computer Assisted Sperm Analysis) systems, imaging systems, consumables, and services for assisted reproductive technology (ART) and developmental biology research. For over 30 years, the company has served IVF clinics, fertility centers, animal breeding operations, pharmaceutical companies, and research laboratories worldwide. Core products include sperm analyzers that measure motility and morphology; AI-enabled laser systems for embryo manipulation and selection; the Oosight Imaging System for oocyte assessment; micropipettes for micromanipulation; embryo culture media; and ancillary lab equipment including air purification systems, incubators, and IVF workstations. Hamilton Thorne's solutions support human fertility treatment, animal reproduction (equine, poultry, livestock), and research applications in toxicology, drug safety, and stem cell development. Manufacturing is ISO-certified and conducted in-house in the USA.

NanoEntek, Inc is a medical device manufacturer specializing in lab-on-a-chip technology that combines MEMS (microelectromechanical systems) and microfluidics. The company designs and manufactures microfluidic analyzers that perform biological analysis using minimal sample volumes in very short timeframes. Their core technology involves engineering microchannels on plastic or glass microfluid chips to control biofluid flow and execute various diagnostic assays. Key product lines include the FREND™ System (microfluidic immunofluorescence analyzer), EVE™ HT FL (high-throughput fluorescence cell counter), ADAM™ MC Plus (fluorescence cell counter), ADAM™ rWBC HT (residual white blood cell counter), and ADAMII™ CD34 (fluorescence CD34 counter). These instruments are designed for clinical laboratory and life-science research applications, including cell counting, immunoassays, and hematology analysis. NanoEntek maintains a global distribution and partnership network, with presence at major industry trade shows including Analytica and WHX Labs. The company holds multiple FDA 510(k) clearances and patents related to microfluidic technology. Manufacturing and quality standards align with in vitro diagnostics (IVD) regulatory requirements. The company serves clinical laboratories, research institutions, and diagnostic facilities worldwide.

KBMO Diagnostics is a clinical laboratory specializing in advanced diagnostic testing for food sensitivities and gut health. The company offers the FIT (Food Inflammation Test), a patented, multi-pathway delayed food sensitivity test that measures both IgG antibodies and immune complexes—the primary food-related immune pathways. KBMO's tests are designed for healthcare providers to identify food reactivities that contribute to inflammation, autoimmune conditions, and chronic diseases including skin rashes, intestinal disorders, brain fog, and arthritis. The company provides fingerstick bloodspot collection kits for at-home testing, comprehensive personalized reports, and practitioner tools including rotation diet recommendations and integration with supplement dispensing platforms (Fullscript). KBMO also offers complementary protocols (NutriDyn, Microbiome, Biotics) to support clinical outcomes. Services target functional medicine practitioners, naturopaths, nutritionists, and chiropractors seeking actionable patient data for personalized therapeutic interventions.

Nova Biomedical is a privately held, globally-leading in vitro diagnostic (IVD) company founded in 1976 and headquartered in Waltham, Massachusetts. The largest privately owned diagnostic company in the United States, Nova Biomedical employs over 1,500 people across manufacturing facilities in Massachusetts and Taipei, Taiwan, serving 110+ countries through its global distributor network. The company specializes in advanced blood testing and analytical instrumentation, with a comprehensive portfolio including critical care blood gas analyzers (StatProfile® Prime series), point-of-care glucose meters (StatStrip®, NovaMax®), cell culture analyzers (BioProfile® Flex), clinical and bioprocessing osmometers, liquid volume verification systems, and automated CSF cell counters. Nova Biomedical serves hospitals, emergency departments, blood banks, biotech/pharmaceutical manufacturers, clinical research laboratories, and veterinary diagnostics markets. The company operates through multiple trusted brand portfolios including Advanced Instruments, BioProfile, StatProfile, StatStrip, Artel, Solentim, and GloCyte, delivering solutions for bioprocessing, clinical diagnostics, and veterinary applications with emphasis on improving patient outcomes and operational efficiency.

Fortis Life Sciences is a strategic platform company based in Waltham, Massachusetts, founded in August 2020. It operates as a multi-subsidiary life sciences tools provider delivering specialized reagents, diagnostic components, and custom development services to biopharma, diagnostics, and research organizations globally. The company integrates five ISO 13485 certified and GMP-compliant North American manufacturing and R&D locations under its "Farm-to-Bench" system, spanning antibody discovery and production, viral vector manufacturing, nanoparticle synthesis, molecular biology reagents, and diagnostic component CDMO services. Core product portfolio includes premium monoclonal and recombinant antibodies (validated for ELISA, Western blot, IHC, flow cytometry, spatial biology), VHH domain libraries (AbNano platform), lateral flow immunoassay components, assay-grade enzymes and master mixes, diagnostic grade nanoparticles (gold, platinum, silica), and lentiviral and AAV vector production. The company also offers contract manufacturing, antibody development, spatial biology imaging services, and precision lyophilization for stable diagnostic products. It serves over 10,000 customers across biopharma, diagnostics OEMs, contract manufacturers, academic research, and applied technology sectors.

Bruker Corporation is a global leader in high-performance scientific instruments and analytical solutions for life sciences research and diagnostics. The company manufactures a broad portfolio of analytical instruments including nuclear magnetic resonance (NMR) spectrometers, X-ray fluorescence (XRF) spectrometers, Fourier-transform infrared (FT-IR) and Raman spectrometers, electron paramagnetic resonance (EPR) systems, and advanced microscopy platforms. Bruker's diagnostic division offers the MALDI Biotyper® and IR Biotyper® systems for microbial identification, as well as the MyGenius PRO® molecular diagnostics system for sample-to-answer PCR-based infectious disease testing. The company also provides spatial biology platforms for multi-omics analysis (DNA, RNA, protein) and light-sheet microscopy systems such as the Papilio5D for 3D cell culture imaging. Bruker serves academia, biopharma, clinical diagnostics, and industrial markets globally. Products include handheld XRF analyzers (TITAN), bench-top vacuum FT-IR spectrometers (VERTEX NEO Ultra), nanomechanical testing systems (Hysitron PI Envision), and specialty analyzers for dairy and food quality control (MOVE-T). The company maintains significant R&D capabilities and offers comprehensive customer support services, consumables, accessories, and software through the Bruker Store. Bruker operates manufacturing and R&D facilities in Billerica, Massachusetts, and globally.

SEKISUI Diagnostics is a global leader in diagnostic reagents, biochemistry products, and point-of-care testing solutions with over 40 years of industry experience. The company manufactures and supplies clinical chemistry reagents, performing over 1.8 billion tests annually worldwide. Core product lines include Clinical Chemistry reagents for laboratory analyzers, Point-of-Care Testing (POCT) solutions in multiple formats to enable rapid diagnosis in office and clinic settings, and specialty biochemical enzymes for diagnostic reagent and biosensor manufacturers. SEKISUI also provides Blood Collection Tube Raw Materials and pre-analytic systems for plasma collection tubes, serving blood collection manufacturers globally. The Metrix® COVID/Flu Test represents their molecular diagnostics portfolio, offering point-of-care detection and differentiation of SARS-CoV-2, Flu A, and Flu B with small footprint and streamlined workflow. Beyond products, SEKISUI offers Biopharma Services supporting biotherapeutic and pharmaceutical manufacturing, technical transfer, and process scale-up. The company serves core laboratories, healthcare providers, in vitro diagnostics manufacturers, and distributors. SEKISUI combines analytical accuracy with operational efficiency, positioning products for cost containment and outcome improvement across clinical settings. The organization emphasizes patient-centric diagnostic solutions and maintains comprehensive technical and educational support for laboratory and clinical professionals.

Haemonetics Corporation is a global medical technology company headquartered in Boston, Massachusetts, specializing in blood management, plasma collection, and vascular closure solutions for hospitals, blood centers, and plasma donation centers. The company develops innovative devices and software platforms that improve patient care quality, clinical outcomes, and operational efficiency across transfusion medicine and interventional procedures. Product portfolio includes blood collection and processing systems, plasma collection platforms, blood testing and safety solutions, and vascular closure devices. The company serves three primary market segments: hospitals (advancing surgical and critical care outcomes), blood centers (optimizing collection efficiency and blood component availability), and plasma centers (enhancing donor experience and collection yield). Haemonetics maintains FDA clearances and approvals for its portfolio, as evidenced by recent FDA approvals including expanded labeling for the VASCADE MVP® XL Venous Vascular Closure System and FDA clearance for the NexSys® PCS Plasma Collection System with Persona® PLUS Technology. The company is publicly traded and demonstrates commitment to regulatory compliance, operational excellence, and continuous innovation in transfusion medicine and interventional vascular technologies. Manufacturing and service capabilities span device production, software platforms, and customer support infrastructure.